Fosinopril: A Reappraisal of its Pharmacology and Therapeutic Efficacy in Essential Hypertension

Drugs

Volumn 51, Issue 5, 1996, Pages 777-791

  Wagstaff, Antona J ^a   Davis, Rick ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; FOSINOPRILAT; HYDROCHLOROTHIAZIDE; ISRADIPINE; NIFEDIPINE; PHOSPHINIC ACID DERIVATIVE; PROPRANOLOL; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HUMAN; LIVER CLEARANCE; ORAL DRUG ADMINISTRATION; REVIEW; URINARY EXCRETION; VERTIGO;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; FOSINOPRIL; HUMANS; HYPERTENSION;

EID: 0029963941     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00006     Document Type: Review

References (75)

1. Murdoch D, McTavish D. Fosinopril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992 Jan; 43: 123-40
2. Weber MA. Cardiovascular effects of angiotensin-converting enzyme inhibition: experience with fosinopril. Drugs Today 1993 Sep; 29: 421-30
3. Duchin KL, Waclawski AP, Tu JI, et al. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. J Clin Pharmacol 1991 Jan; 31: 58-64
4. Forslund T, Franzen P, Backman R. Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. J Intern Med 1991 Dec; 230: 511-7
5. Gehr T, Sica D, Grasela D, et al. Pharmacodynamics of fosinopril in chronic ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients [abstract]. Clin Pharmacol Ther 1991 Feb; 49: 194
6. Keilani T, Schlueter W, Molteni A, et al. Converting enzyme inhibition with fosinopril does not suppress plasma aldosterone and may not cause hyperkalemia despite moderate renal impairment [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 245
7. Keilani T, Schlueter W, Batlle D. Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995; 35: 87-97
8. Ford NF, Fulmor IE, Nichola PS, et al. Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. Clin Cardiol 1993 Apr; 16: 324-30
9. Fortini A, Cappelletti C, Cecchi L, et al. Fosinopril in the treatment of hypertension: effects on 24h ambulatory blood pressure and on blood pressure response to exercise. J Hum Hypertens 1994 Jun; 8: 469-74
10. Beaulieu M, Nadeau A, Lacourcière Y, et al. Post-exercise reduction in blood pressure in hypertensive subjects: effects of angiotensin converting enzyme inhibition. Br J Clin Pharmacol 1993 Oct; 36: 331-8
11. Pool JL, Cushman W, Saini R, et al. Seventeen cell, factorial design trial of multiple dose combinations (DC) of fosinopril (Fos) and hydrochlorothiazide (HCTZ) in mild to moderate hypertension (HTN) [abstract]. Am J Hypertens 1994 Apr; 7 (Part 2): 42A
12. Andersson P-E, Andren B, Lind L, et al. Change in left ventricular wall thickness and skeletal muscle blood flow during antihypertensive treatment with fosinopril [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: 76
13. Gaudio C, Tanzilli G, Collatina S, et al. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with fosinopril by magnetic resonance imaging [abstract]. J Heart Fail 1993 May; 1 Suppl.: 391
14. Veglio F, Gastaldi L, Melchio R, et al. 24-h BP and left ventricular mass after long-term therapy with fosinopril [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 185
15. Oren S, Messerli FH, Grossman E. Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension. J Am Coll Cardiol 1991 Apr; 17: 1183-7
16. Palazzuoli V, Mondillo S, D'Aprile N, et al. Myocardial hypertrophy: effects of treatment with fosinopril evaluated by echocardiography. Eur J Clin Res 1994; 5: 203-8
17. Zusman RM, Christensen DM, Higgins J, et al. Effects of fosinopril on cardiac function in patients with hypertension: radionuclide assessment of left ventricular systolic and diastolic performance. Am J Hypertens 1992 Apr; 5 (Pt 1): 219-23
18. Paulson OB, Waldemar G, Strandgaard S. Fosinopril and cerebral blood flow. Rev Contemp Pharmacother 1993; 4: 35-44
19. Paulson OB, Waldemar G, Andersen AR, et al. Role of angiotensin in autoregulation of cerebral blood flow. Circulation 1988; 77 Suppl. 1: 155-8
20. Pedersen EV, Bobkiewcz-Kozlowska T, Waldemar G, et al. The renin angiotensin of cerebral arteries contributes to cerebrovuscular resistance [abstract]. Eur J Clin Invest 1987; 17: A38
21. Waldemar G, Ibsen H, Strandgaard S, et al. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. Am J Hypertens 1990 Jun; 3: 464-70
22. Semplicini A, Simonella C, Meneghetti G, et al. Effects of fosinopril and hydrochlorothiazide on cerebral perfusion in uncomplicated essential hypertension. J Hypertens 1993 Dec; 11 Suppl. 5: s372-3
23. Arrighi P, Giovannetti R, Salvetti A. Comparison of renal hemodynamic effects of benazepril and fosinopril in essential hypertensives [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 66A
24. Beck S, Jungmann E, Haak T, et al. Comparative study on the effect of molsidomine, nitrendipine and fosinopril on renal and hormonal responses to physical exercise in type 1 diabetes mellitus [abstract]. Eur J Clin Invest 1993; 23 Suppl. 1: A8
25. Lacourcière Y, Nadeau A, Poirier L, et al. Effects of amlodipine and fosinopril alone and in combination on renal function in hypertensive NIDDM patients without clinical nephropathy [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 137
26. Füsgen I, Fassbinder W, Foerster H-M, et al. Fosinopril - 2 years in practice: experiences in about 30 000 patients [in German]. Fortschr Med 1994; 112 Suppl. 165: 2-11
27. Loguercio C, Piscopo P, Guerriero C. Evaluation of global liver function after fosinopril treatment of hypertensive patients with liver cirrhosis [in Italian]. Clin Ter 1994 Dec; 145: 475-9
28. Allemann Y, Baumann S, Jost M, et al. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. Eur J Clin Pharmacol 1992 Mar; 42: 275-80
29. Keilani T, Schlueter WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993 Feb 15; 118: 246-54
30. Benzi L, Ciccarone A, Cecchetti P, et al. Effects of angiotensin converting enzyme inhibition (ACE-1) with fosinopril on cellular insulin metabolism in patients with non insulin dependent diabetes mellitus (NIDDM-P) and hypertension [abstract]. Diabetes 1994; 43 Suppl. 1: 221
31. Reneland R, Andersson P-E, Haenni A, et al. Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 1994; 46 (5): 431-6
32. Tan SA, Tan LG, Berk LS. Effects of fosinopril and ramipril on β-endorphin levels in hypertensive diabetics [abstract]. Chest 1992 Aug; 102 Suppl. 2: 53
33. Hui KK, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991 Apr; 49: 457-67
34. Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988 Jan; 25: 9-15
35. Salvetti A, Newer ACE inhibitors: a look at the future. Drugs 1990 Dec; 40: 800-28
36. Gehr TWB, Sica DA, Grasela DM. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. Eur J Clin Pharmacol 1993; 45 (5): 431-6
37. Sica D, Davis J, Fakhry I, et al. Fosinopril sodium (FS) pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD) [abstract]. Kidney Int 1989; 35 (1): 277
38. Ford NF, Lasseter KC, Van Harken DR, et al. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 1995 Feb; 35: 145-50
39. Sica DA, Cutler RE, Parmer RJ, et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991 May; 20: 420-7
40. Gehr TWB, Sica DA, Grasela DM, et al. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 1991 Aug; 41: 165-9
41. Duchin K, Kripalani K, Kramer P, et al. Disposition and pharmacodynamics of fosinopril sodium (FS) and its diacid in hemodialysis (HD) patients [abstract]. Kidney Int 1989; 35 (1): 245
42. Levinson B, Sugerman AA, Couchman T, et al. Advanced age per se has no influence on the kinetics of the active diacid of fosinopril [abstract]. J Clin Pharmacol 1986; 26: 555
43. Hoyer J, Schulte K-L, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 1993 Mar; 24: 230-54
44. Duchin KL. Clinical pharmacology of fosinopril. Drug Invest 1991; 3 Suppl. 4: 12-7
45. Kelly JG, O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors: a review. Clin Pharmacokinet 1990 Sep; 19: 177-96
46. MacLeod CM, Bartley EA, Kripilani KJ, et al. Effect of hepatic function on disposition of fosinopril in humans [abstract]. J Clin Pharmacol 1990 Sep; 30: 839
47. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990 Sep; 40: 326-45
48. Burris JF. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 1995; 35: 337-42
49. Anderson RJ, Duchin KL, Gore RD, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991 May; 17: 636-42
50. Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther 1990 Nov-Dec; 12: 520-33
51. Mion D Jr, Lima E Jr, Almeida FA, et al. Fosinopril once a day in mild and moderate hypertension. Brazilian multicenter trial [in Spanish]. Arq Bras Cardiol 1993; 60 (3): 203-8
52. Martin LC, Velasco-Cornejo IF, Franco RJ. Treatment of mild and moderate hypertension with fosinopril. Comparison of adverse effects with other antihypertensive agents [in Portuguese]. Arq Bras Cardiol 1994 May; 62: 369-74
53. Miller WE. Randomised, double-blind, comparison of fosinopril and propranolol added to diuretic therapy for the treatment of moderate-to-severe hypertension. Drug Invest 1991; 3 Suppl. 4: 32-7
54. Romero R, Honorato J. Randomized, double blind comparison of fosinopril (FOS) sodium and propranolol (PRO) added to diuretic therapy for the treatment of moderate to severe essential hypertension [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 309
55. Seedat YK, Parag KB. Comparison of fosinopril and propranolol combined with chlorthalidone in the treatment of moderately to severely hypertensive Black and Indian patients. Curr Ther Res 1992 Jun; 51: 830-8
56. Mancia G, Omboni S, IPSIS Study Group. Antihypertensive efficacy of amlodipine vs fosinopril as assessed by 48 hour ambulatory blood pressure monitoring in isolated systolic hypertension [abstract no. 501]. In: Seventh European Meeting on Hypertension; 1995 9-12 Jun; Milan, Italy. Milan: European Society of Hypertension, 1995: 115
57. Guthrie R, Plesher DM, Saini R. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in patients with mild-to-moderate hypertension [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 39A
58. Perticone F, Pugliese F, Marcantonio AM, et al. Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril:a double-blind crossover study by means of ambulatory blood pressure monitoring. Clin Cardiol 1995 Jul; 18: 401-7
59. Clementy J. Double-blind, randomised study of fosinopril vs nifedipine SR in the treatment of mild-to-moderate hypertension in elderly patients. Drug Invest 1991; 3 Suppl. 4: 45-53
60. Goldstein RJ. A multicentre, randomised, double-blind, parallel comparison of fosinopril sodium and enalapril maleate for the treatment of mild-to-moderate essential hypertension. Drug Invest 1991; 3 Suppl. 4: 38-44
61. Williams L, Davis J, Lowenthal DT, et al. The effect of fosinopril (F) or verapamil SR (V) with or without diuretic (HCTZ) in elderly hypertensive males (EHM) [abstract]. Am J Hypertens 1993 May; 6 (Pt 2): 104A
62. Fillastre JP, Hermant S, Huynen P, et al. Efficacy of the combination of fosinopril (Fo) 10 mg and hydrochlorothiazide (HCTZ) 12.5 mg in elderly hypertensive patients [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 187
63. Fernández, M, Madero R, Gonzaléz D, et al. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension 1994 Jan; 23 Suppl. I:I-207-10
64. Hermant S, Huynen P, Boussac J, et al. A double-blind comparison of the combination of fosinopril and hydrochlorothiazide (FO/HCTZ) with nifedipine S.R. (NIF) in the treatment of mild to moderate hypertension [abstract]. Am J Hypertens 1995 Apr; 8 (Pt 2): 190
65. Pasic J, Hui KK, Yu JL. Comparison of 24-hour blood pressure control during combination therapy with chlorthalidone and fosinopril or propranolol in patients with moderate to severe hypertension [abstract]. Am J Hypertens 1992 May; 5 (Pt 2): 90A
66. Levinson B, Graney WF, DeVault AR, et al. Age is not a reason for dose adjustment of fosinopril in hypertension [abstract no. 1029]. Am J Hypertens 1989 May; 2 (5 Pt 2): 8A
67. Johnson KA, Denis J, Lazar JM. Cost and potency comparison of angiotensin converting enzyme inhibitor therapy in ambulatory hypertensive patients [abstract]. Pharmacotherapy 1995 Jan-Feb; 15: 117
68. BMS cuts Staril 20mg price in UK. Scrip 1996 January 16; 2094: 22
69. Sharif MN, Evans BL, Pylypchuk GB. Cough induced by quinapril with resolution after changing to fosinopril. Ann Pharmacother 1994 Jun; 28: 720-2
70. Antonios TFT, MacGregor GA. Antiotensin converting enzyme inhibitors in hypertension: potential problems. J Hypertens 1995; 13 Suppl. 3: S11-6
71. Germino FW, Lastra J, Pool P, et al. Evaluation of the cough profile of fosinopril in hypertensive patients with ACE inhibitor-associated cough - a pilot study. Curr Ther Res 1993 Nov; 54: 469-75
72. David D, Jallad N, Germino FW, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther 1995 Oct; 2: 806-13
73. Bristol-Myers Squibb Company. Fosinopril sodium tablets prescribing information. Princeton, New Jersey, USA, 1995.
74. Reisin E. Recommendations for the evaluation and treatment of high blood pressure: a review of six national and international reports. Drugs Today 1995; 31 (6): 427-32
75. Binder SB. ACE inhibitors: review of four new agents. Am Fam Physician 1993 Oct 1; 48: 851-7